Leonard Appleman is an Oncology physician affiliated with University of Pittsburgh. OpenAlex indexes 349 publications with 6,390 citations (h-index 42); ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5115 Centre Ave
Pittsburgh, PA 152321301
Telephone
412-692-4724Provider last certified this registry record 26 Jan 2023.
Clinical trials
- Circulating Tumor DNA in High Risk Localized Prostate Cancer
Sponsor: University of Pittsburgh
- Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Sponsor: National Cancer Institute (NCI)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20252 payments
- Janssen Biotech, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48%Cytochrome P450 17A1 Inhibitor19.2%Abiraterone Acetate100%Part D≥43 patientsAndrogen Receptor Inhibitor15.2%Xtandi89%Bicalutamide11%Part D≥32 patients+ 5 more classes in this area
Metabolism & gastrointestinal
32.2%Corticosteroid26.9%Prednisone100%Part D≥85 patientsPotassium supplement3%Potassium Chloride100%Part D≥14 patients+ 1 more class in this area
Nervous system
9%Benzodiazepine3%Clonazepam38%Alprazolam36%Lorazepam26%Part D<11 patientsGabapentinoids2.4%Gabapentin100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2015–2026 per NIH RePORTER. The latest:
- Protocol Review and Monitoring System
University of Pittsburgh at Pittsburgh
FY2026$102,757P30CA047904
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors
JNCI Journal of the National Cancer Institute
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Toren Finkel, MD/PHD
University of Pittsburgh
Sally Wenzel, MD
University of Pittsburgh
Mary Phillips, MD
University of Pittsburgh
Jared Magnani, MD, MSc
University of Pittsburgh
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”